Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of “Moderate Buy” by Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has received a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $104.4444.

IRON has been the subject of several analyst reports. Wedbush reaffirmed an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Finally, Morgan Stanley upped their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th.

Disc Medicine Trading Up 3.6%

Disc Medicine stock opened at $79.76 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of -12.05 and a beta of 0.97. Disc Medicine has a 1 year low of $40.00 and a 1 year high of $99.50. The firm’s 50 day moving average price is $69.75 and its two-hundred day moving average price is $70.13.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). On average, research analysts predict that Disc Medicine will post -6.74 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In related news, insider Rahul Khara sold 1,649 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $123,675.00. Following the completion of the sale, the insider owned 52,173 shares in the company, valued at approximately $3,912,975. This represents a 3.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John D. Quisel sold 34,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the completion of the transaction, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $15,871,953.44. This represents a 13.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 85,000 shares of company stock valued at $5,956,865 over the last three months. 3.76% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IRON. Assenagon Asset Management S.A. grew its stake in Disc Medicine by 3,329.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after acquiring an additional 347,403 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in shares of Disc Medicine in the third quarter worth approximately $6,752,000. SG Americas Securities LLC lifted its position in shares of Disc Medicine by 161.9% in the fourth quarter. SG Americas Securities LLC now owns 21,122 shares of the company’s stock worth $1,677,000 after purchasing an additional 13,058 shares in the last quarter. First Light Asset Management LLC acquired a new stake in shares of Disc Medicine during the third quarter worth approximately $15,277,000. Finally, NEXTBio Capital Management LP purchased a new position in Disc Medicine during the fourth quarter valued at approximately $3,397,000. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.